Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) saw strong trading volume on Friday . 413,080 shares changed hands during trading, a decline of 47% from the previous session’s volume of 773,235 shares.The stock last traded at $15.54 and had previously closed at $14.96.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday. Maxim Group lifted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Stock Up 5.3 %

The firm’s 50-day moving average is $16.82 and its 200-day moving average is $10.81. The company has a market capitalization of $716.61 million, a PE ratio of -14.87 and a beta of 3.98.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently bought and sold shares of the company. Main Street Financial Solutions LLC lifted its position in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Capricor Therapeutics during the third quarter valued at about $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics in the second quarter worth $147,000. The Manufacturers Life Insurance Company bought a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC bought a new position in Capricor Therapeutics during the 3rd quarter valued at approximately $192,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.